GSK enters agreement to acquire IDRx, Inc.

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc.

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

gsk.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Business Wire

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

businesswire.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Regulatory News

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

lse.co.uk

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. – Company …

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

ft.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Morningstar

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

morningstar.com

$1
OFF

IDRx To Be Acquired By GSK For $1 Billion Upfront, And Additional …

2 weeks from now

3 days ago · The Public M&A and Life Sciences teams advised IDRx, Inc. on its agreement to be acquired by GSK plc (LSE/NYSE: GSK) for $1 billion upfront, with potential for an additional …

goodwinlaw.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - MarketScreener

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

marketscreener.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. – IDRx

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

idrx.com

$1.15
OFF

GSK To Acquire GIST Drug Developer IDRx For Up To $1.15 Bln Cash

2 weeks from now

2 days ago · (RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical …

nasdaq.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Company …

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

investegate.co.uk

100%
OFF

2025-01-13 | GSK Enters Agreement To Acquire IDRx, Inc.

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

stockhouse.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - Stocktitan.net

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

stocktitan.net

100%
OFF

GSK PLC GSK Enters Agreement To Acquire IDRx, Inc. - ADVFN

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

advfn.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Shares Magazine

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

sharesmagazine.co.uk

$1
OFF

Stock-exchange Announcement - GSK

2 weeks from now

GSK enters agreement to acquire IDRx, Inc. • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor ... an upfront payment of $1 billion with potential for an additional $150 …

gsk.com

$1.15
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | GSK - MarketScreener

2 weeks from now

2 days ago · - Acquisition adds to GSK's growing portfolio in gastrointestinal (GI) cancers - GSK to pay up to $1.15 billion. London, UK-- GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) …

marketscreener.com

FAQs about GSK enters agreement to acquire IDRx, Inc. Coupon?

Is GSK acquiring idrx?

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion in cash. ...

Who owns idrx in JP Morgan 2025?

"JP Morgan 2025: GSK acquires IDRx in $1.15bn deal " was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. ...

Will idrx-42 revolutionize Gist treatment in 2025?

Tony Wood, Chief Scientific Officer, GSK, said, "We are excited by the early data from IDRX-42 and its unique ability to target all clinically relevant KIT mutations present in GIST, a major gap in the current standard of care. We look forward to accelerating its development in 2025 to redefine treatment." ...

How much will GSK pay upfront?

Under the agreement signed by both companies, GSK (GSK) will pay $1 billion upfront, with the potential for an additional $150 million success-based regulatory approval milestone payment. Th... ...

Is idrx-42 a tyrosine kinase inhibitor for gastrointestinal stromal tumor?

The acquisition includes lead molecule IDRX-42, which is a highly selective KIT Tyrosine Kinase Inhibitor being developed as a first- and second-line therapy for treating gastrointestinal stromal tumors or GIST. ...

When is GSK presenting at JP Morgan Healthcare Conference 2025?

GSK is due to present at the JP Morgan Healthcare Conference 2025 on 14 January. The conference is taking place in San Francisco, US, between 13 and 16 January. "JP Morgan 2025: GSK acquires IDRx in $1.15bn deal " was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. ...